{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:03:49Z","timestamp":1777871029370,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/T015969\/1"],"award-info":[{"award-number":["MR\/T015969\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014054","name":"Drugs for Neglected Diseases initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006393","name":"Universidad de Granada","doi-asserted-by":"publisher","award":["PP2023.PRI.I.14"],"award-info":[{"award-number":["PP2023.PRI.I.14"]}],"id":[{"id":"10.13039\/501100006393","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ram\u00f3n Areces","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Antimicrob Resist"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Infections with the protozoan parasite\n                    <jats:italic>Trypanosoma cruzi<\/jats:italic>\n                    are widespread in the Americas and can lead to severe cardiac and\/or gastrointestinal pathology. Current treatments are limited to monotherapies characterised by prolonged dosing regimens, disputed efficacy and toxic side-effects. Sterile cure is often confounded by persistence of a small sub-population of parasites that display increased drug tolerance. Here, we demonstrate that short duration co-administration of well-tolerated sub-efficacious oral doses of the parasite-selective proteasome inhibitor GNF6702 and the pro-drug benznidazole produce parasitological cure in an experimental model of chronic Chagas disease.\n                  <\/jats:p>","DOI":"10.1038\/s44259-026-00205-8","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:57:51Z","timestamp":1777568271000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overcoming Trypanosoma cruzi persistence with a mechanistically distinct drug combination"],"prefix":"10.1038","volume":"4","author":[{"given":"Amanda Fortes","family":"Francisco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Olmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Escudi\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Chatelain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"205_CR1","first-page":"Doc33","volume":"20","author":"M Michalik","year":"2025","unstructured":"Michalik, M. et al. Advances and prospects for treatment strategies of drug-resistant tuberculosis: a review. GMS Hyg. Infect. Control 20, Doc33 (2025).","journal-title":"GMS Hyg. Infect. Control"},{"key":"205_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pt.2020.09.011","volume":"37","author":"RW van der Pluijm","year":"2021","unstructured":"van der Pluijm, R. W. et al. Triple artemisinin-based combination therapies for malaria\u2014a new paradigm? Trends Parasitol. 37, 15\u201324 (2021).","journal-title":"Trends Parasitol."},{"key":"205_CR3","first-page":"e91933","volume":"17","author":"C Iheagwara","year":"2025","unstructured":"Iheagwara, C. et al. The latest trends and evolution of HIV medication management: a systematic review. Cureus 17, e91933 (2025).","journal-title":"Cureus"},{"key":"205_CR4","unstructured":"World Health Organization. Chagas disease (also known as American trypanosomiasis). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chagas-disease-(american-trypanosomiasis) (2025)."},{"key":"205_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3389\/fpubh.2019.00166","volume":"7","author":"KCF Lidani","year":"2019","unstructured":"Lidani, K. C. F. et al. Chagas disease: from discovery to a worldwide health problem. Front. Public Health 7, 166 (2019).","journal-title":"Front. Public Health"},{"key":"205_CR6","first-page":"101266","volume":"52","author":"S Vucetich","year":"2025","unstructured":"Vucetich, S. et al. Estimating the health and economic burden of Chagas cardiomyopathy in the United States: a population-based analysis. Lancet Reg. Health Am. 52, 101266 (2025).","journal-title":"Lancet Reg. Health Am."},{"key":"205_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01787-7","volume":"403","author":"AS de Sousa","year":"2024","unstructured":"de Sousa, A. S. et al. Chagas disease. Lancet 403, 203\u2013218 (2024).","journal-title":"Lancet"},{"key":"205_CR8","first-page":"100832","volume":"37","author":"MCP Nunes","year":"2024","unstructured":"Nunes, M. C. P. et al. Clinical features of Chagas disease progression and severity. Lancet Reg. Health Am. 37, 100832 (2024).","journal-title":"Lancet Reg. Health Am."},{"key":"205_CR9","doi-asserted-by":"publisher","first-page":"5022","DOI":"10.1073\/pnas.0711014105","volume":"105","author":"SR Wilkinson","year":"2008","unstructured":"Wilkinson, S. R. et al. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc. Natl. Acad. Sci. USA 105, 5022\u20135027 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"205_CR10","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.3390\/molecules25122799","volume":"25","author":"AF Francisco","year":"2020","unstructured":"Francisco, A. F. et al. Challenges in Chagas disease drug development. Molecules 25, 2799 (2020).","journal-title":"Molecules"},{"key":"205_CR11","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.2174\/1381612827666210216152654","volume":"27","author":"AA Zuma","year":"2021","unstructured":"Zuma, A. A. & de Souza, W. Chagas disease chemotherapy: What do we know so far? Curr. Pharm. Des. 27, 3963\u20133995 (2021).","journal-title":"Curr. Pharm. Des."},{"key":"205_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1128\/AAC.05135-11","volume":"56","author":"BS Hall","year":"2012","unstructured":"Hall, B. S. & Wilkinson, S. R. Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation. Antimicrob. Agents Chemother. 56, 115\u2013123 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"205_CR13","doi-asserted-by":"publisher","first-page":"e2844","DOI":"10.1371\/journal.pntd.0002844","volume":"8","author":"A Trochine","year":"2014","unstructured":"Trochine, A. et al. Benznidazole biotransformation and multiple targets in Trypanosoma cruzi revealed by metabolomics. PLoS Negl. Trop. Dis. 8, e2844 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"205_CR14","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1007\/BF01941187","volume":"44","author":"EG Diaz de Toranzo","year":"1988","unstructured":"Diaz de Toranzo, E. G. et al. Interaction of benznidazole reactive metabolites with nuclear and kinetoplastic DNA, proteins and lipids from Trypanosoma cruzi. Experientia 44, 880\u2013881 (1988).","journal-title":"Experientia"},{"key":"205_CR15","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.cbpa.2006.03.004","volume":"146","author":"JD Maya","year":"2007","unstructured":"Maya, J. D. et al. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp. Biochem. Physiol. A. Mol. Integr. Physiol. 146, 601\u2013620 (2007).","journal-title":"Comp. Biochem. Physiol. A. Mol. Integr. Physiol."},{"key":"205_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14986-6","volume":"7","author":"MC Campos","year":"2017","unstructured":"Campos, M. C. Genome-wide mutagenesis and multi-drug resistance in American trypanosomes induced by the front-line drug benznidazole. Sci. Rep. 7, 14407 (2017).","journal-title":"Sci. Rep."},{"key":"205_CR17","doi-asserted-by":"publisher","first-page":"e1011627","DOI":"10.1371\/journal.ppat.1011627","volume":"19","author":"S Jayawardhana","year":"2023","unstructured":"Jayawardhana, S. et al. Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice. PLoS Pathog. 19, e1011627 (2023).","journal-title":"PLoS Pathog."},{"key":"205_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nature19339","volume":"537","author":"S Khare","year":"2016","unstructured":"Khare, S. et al. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. Nature 537, 229\u2013233 (2016).","journal-title":"Nature"},{"key":"205_CR19","doi-asserted-by":"publisher","first-page":"e0006388","DOI":"10.1371\/journal.pntd.0006388","volume":"12","author":"FC Costa","year":"2018","unstructured":"Costa, F. C. et al. Expanding the toolbox for Trypanosoma cruzi: a parasite line incorporating a bioluminescence-fluorescence dual reporter and streamlined CRISPR\/Cas9 functionality for rapid in vivo localisation and phenotyping. PLoS Negl. Trop. Dis. 12, e0006388 (2018).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"205_CR20","doi-asserted-by":"publisher","first-page":"6930","DOI":"10.3390\/ijms22136930","volume":"22","author":"CB Scarim","year":"2021","unstructured":"Scarim, C. B. et al. Image-based in vitro screening reveals the trypanostatic activity of hydroxymethylnitrofurazone against Trypanosoma cruzi. Int. J. Mol. Sci. 22, 6930 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"205_CR21","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/cmi.12297","volume":"16","author":"MD Lewis","year":"2014","unstructured":"Lewis, M. D. et al. Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection. Cell. Microbiol. 16, 1285\u20131300 (2014).","journal-title":"Cell. Microbiol."},{"key":"205_CR22","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1126\/science.adh0614","volume":"380","author":"SPS Rao","year":"2023","unstructured":"Rao, S. P. S. et al. Cyanotriazoles are selective topoisomerase II poisons that rapidly cure trypanosome infections. Science 380, 1349\u20131356 (2023).","journal-title":"Science"},{"key":"205_CR23","doi-asserted-by":"publisher","first-page":"eadg8105","DOI":"10.1126\/scitranslmed.adg8105","volume":"15","author":"S Gonz\u00e1lez","year":"2023","unstructured":"Gonz\u00e1lez, S. et al. Short-course combination treatment for experimental chronic Chagas disease. Sci. Transl. Med. 15, eadg8105 (2023).","journal-title":"Sci. Transl. Med."},{"key":"205_CR24","doi-asserted-by":"publisher","first-page":"e01242","DOI":"10.1128\/mBio.01242-20","volume":"11","author":"AI Ward","year":"2020","unstructured":"Ward, A. I. et al. In vivo analysis of Trypanosoma cruzi persistence foci at single-cell resolution. mBio. 11, e01242\u201320 (2020).","journal-title":"mBio."},{"key":"205_CR25","doi-asserted-by":"publisher","first-page":"e0012968","DOI":"10.1371\/journal.pntd.0012968","volume":"19","author":"F Assmus","year":"2025","unstructured":"Assmus, F. et al. Pharmacokinetic-pharmacodynamic modeling of benznidazole and its antitrypanosomal activity in a murine model of chronic Chagas disease. PLoS Negl. Trop. Dis. 19, e0012968 (2025).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"205_CR26","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","volume":"370","author":"I Molina","year":"2014","unstructured":"Molina, I. et al. Randomized trial of posaconazole and benznidazole for chronic Chagas disease. N. Eng. J. Med. 370, 1899\u20131908 (2014).","journal-title":"N. Eng. J. Med."},{"key":"205_CR27","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1056\/NEJMoa1507574","volume":"373","author":"CA Morillo","year":"2015","unstructured":"Morillo, C. A. et al. Randomized trial of benznidazole for chronic Chagas\u2019 cardiomyopathy. N. Eng. J. Med. 373, 1295\u20131306 (2015).","journal-title":"N. Eng. J. Med."},{"key":"205_CR28","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.jacc.2016.12.023","volume":"69","author":"CA Morillo","year":"2017","unstructured":"Morillo, C. A. et al. Benznidazole and posaconazole in eliminating parasites in asymptomatic T. cruzi carriers: the STOP-CHAGAS trial. J. Am. Coll. Cardiol. 69, 939\u2013947 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"205_CR29","doi-asserted-by":"publisher","first-page":"e0384","DOI":"10.1590\/0037-8682-0384-2022","volume":"56","author":"C V\u00e1zquez","year":"2023","unstructured":"V\u00e1zquez, C. et al. Tolerance and adherence of patients with chronic Chagas disease treated with benznidazole. Rev. Soc. Bras. Med. Trop. 56, e0384\u2013e2022 (2023).","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"205_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/srep35351","volume":"6","author":"AF Francisco","year":"2016","unstructured":"Francisco, A. F. et al. Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage. Sci. Rep. 6, 35351 (2016).","journal-title":"Sci. Rep."}],"container-title":["npj Antimicrobials and Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44259-026-00205-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44259-026-00205-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44259-026-00205-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:57:53Z","timestamp":1777568273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44259-026-00205-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["205"],"URL":"https:\/\/doi.org\/10.1038\/s44259-026-00205-8","relation":{},"ISSN":["2731-8745"],"issn-type":[{"value":"2731-8745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}